[HTML][HTML] Development of the Brazilian anti schistosomiasis vaccine based on the recombinant fatty acid binding protein Sm14 plus GLA-SE adjuvant
M Tendler, M Almeida, A Simpson - Frontiers in immunology, 2015 - frontiersin.org
M Tendler, M Almeida, A Simpson
Frontiers in immunology, 2015•frontiersin.orgData herein reported and discussed refer to vaccination with the recombinant fatty acid
binding protein (FABP) family member of the schistosomes, called Sm14. This antigen was
discovered and developed under a Brazilian platform led by the Oswaldo Cruz Foundation,
from the Health Ministry in Brazil, and was assessed for safety and immunogenicity in
healthy volunteers. This paper reviews past and recent outcomes of developmental phases
of the Sm14-based anti schistosomiasis vaccine addressed to, ultimately, impact …
binding protein (FABP) family member of the schistosomes, called Sm14. This antigen was
discovered and developed under a Brazilian platform led by the Oswaldo Cruz Foundation,
from the Health Ministry in Brazil, and was assessed for safety and immunogenicity in
healthy volunteers. This paper reviews past and recent outcomes of developmental phases
of the Sm14-based anti schistosomiasis vaccine addressed to, ultimately, impact …
Data herein reported and discussed refer to vaccination with the recombinant fatty acid binding protein (FABP) family member of the schistosomes, called Sm14. This antigen was discovered and developed under a Brazilian platform led by the Oswaldo Cruz Foundation, from the Health Ministry in Brazil, and was assessed for safety and immunogenicity in healthy volunteers. This paper reviews past and recent outcomes of developmental phases of the Sm14-based anti schistosomiasis vaccine addressed to, ultimately, impact transmission of the second most prevalent parasitic endemic disease worldwide.
Frontiers